Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Patil, S.
Figlin, R. A.
Hutson, T. E.
Michaelson, M. D.
Negrier, S.
Kim, S. T.
Huang, X.
Motzer, R. J.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] City Hope Comprehens Canc Ctr, Duarte, CA USA
[3] Texas Oncol PA, Baylor Sammons Canc Ctr, Dallas, TX USA
[4] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA
[5] Ctr Leon Berard, F-69373 Lyon, France
[6] Pfizer Oncol, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5042
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Shiva Gupta
    Hyunseon C. Kang
    Jia Sun
    Marc R. Matrana
    Nizar M. Tannir
    Haesun Choi
    Abdominal Radiology, 2020, 45 : 1872 - 1882
  • [22] First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from ASCO 2008
    Wood, L.
    CURRENT ONCOLOGY, 2009, 16 : S26 - S28
  • [23] Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Gupta, Shiva
    Kang, Hyunseon C.
    Sun, Jia
    Matrana, Marc R.
    Tannir, Nizar M.
    Choi, Haesun
    ABDOMINAL RADIOLOGY, 2020, 45 (06) : 1872 - 1882
  • [24] Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC)
    Jonasch, E.
    Bair, A.
    Chen, Y.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).
    Morales, Jose Manuel Ruiz
    Swierkowski, Marcin
    Wells, Connor
    Fraccon, Anna Paola
    La Russa, Francesca
    Donskov, Frede
    Bjarnason, Georg A.
    Lee, Jae-Lyun
    Sim, Hao-Wen
    Beuselinck, Benoit
    Wood, Lori
    Yuasa, Takeshi
    Pezaro, Carmel Jo
    Rini, Brian I.
    Szczylik, Cezary
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma
    Qin, Shu-Kui
    Jin, Jie
    Guo, Jun
    Wang, Jin-Wan
    Zhou, Fang-Dian
    Huang, Yi-Ran
    Ren, Xiu-Bao
    Ye, Ding-Wei
    Pan, Sharon
    Sajben, Peter
    Wang, Qiao
    FUTURE ONCOLOGY, 2018, 14 (18) : 1835 - 1845
  • [27] First-line everolimus followed by second-line sunitinib versus the opposite treatment sequence in patients with metastatic renal cell carcinoma (mRCC)
    Knox, J. J.
    Kay, A. C.
    Schiff, E.
    Hollaender, N.
    Rouyrre, N.
    Ravaud, A.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
    Motzer, R. J.
    Escudier, B.
    Bukowski, R.
    Rini, B. I.
    Hutson, T. E.
    Barrios, C. H.
    Lin, X.
    Fly, K.
    Matczak, E.
    Gore, M. E.
    BRITISH JOURNAL OF CANCER, 2013, 108 (12) : 2470 - 2477
  • [29] Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
    R J Motzer
    B Escudier
    R Bukowski
    B I Rini
    T E Hutson
    C H Barrios
    X Lin
    K Fly
    E Matczak
    M E Gore
    British Journal of Cancer, 2013, 108 : 2470 - 2477
  • [30] Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
    Zhang, Hai-Liang
    Sheng, Xi-Nan
    Li, Xue-Song
    Wang, Hong-Kai
    Chi, Zhi-Hong
    He, Zhi-Song
    Ye, Ding-Wei
    Guo, Jun
    BMC CANCER, 2017, 17
12345